scFv-based biologics show potential for immunomodulation in type 1 and type 2 diabetes

Photo by National Institute of Allergy and Infectious Diseases / Unsplash

Frontiers in Medicine Published June 4, 2026 Medically reviewed June 4, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Interpret scFv-based biologics as an early-stage, preclinical concept for diabetes immunomodulation.

This narrative review examines the emerging role of single-chain variable fragment (scFv)-based biologics in the management of type 1 and type 2 diabetes. The authors discuss the rationale for targeting immune checkpoints such as CTLA-4 and PD-1, as well as insulin-degrading enzyme and GLP-1 receptor, to achieve immunomodulation and metabolic regulation. The review highlights the potential of scFv constructs to offer greater specificity and reduced immunogenicity compared with conventional monoclonal antibodies.

Key findings are qualitative, as no pooled effect sizes or primary outcome data are reported. The authors suggest that scFv-based agents could complement or replace conventional pharmacotherapy by simultaneously addressing autoimmune components in type 1 diabetes and inflammatory pathways in type 2 diabetes. However, the review does not provide specific efficacy or safety data from clinical trials.

The authors acknowledge that the field is in early stages, with most evidence derived from preclinical models. Limitations include the lack of human studies, undefined dosing regimens, and uncharacterized long-term safety profiles. No adverse events or tolerability data are reported.

For clinicians, this review offers a conceptual framework for understanding how scFv biologics might fit into future diabetes care. However, given the absence of clinical trial results, these approaches remain investigational and should not alter current practice.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

The global epidemic of diabetes mellitus the limitations of current therapies-including waning efficacy, adverse effects, and inability to modify disease progression-have accelerated the shift from conventional pharmacotherapy toward biologic agents. This review examines the emergence of single-chain variable fragments (scFv) as a versatile and engineerable class of biotherapeutics for precision diabetes management. Distinguished from full-length monoclonal antibodies (mAbs) by their compact size, enhanced tissue penetration, and modular design, scFv enable precise targeting of both autoimmune and metabolic pathways underlying type 1 diabetes and type 2 diabetes. We summarize advances in scFv applications spanning immunomodulation (e.g., via CTLA-4 and PD-1) and metabolic regulation (e.g., through insulin-degrading enzyme and GLP-1 receptor). Furthermore, we highlight the unique value of avian-derived scFv in recognizing conserved epitopes and overcoming immune tolerance, along with engineering strategies-such as Fc fusion, PEGylation, and multispecific formatting-that enhance pharmacokinetics and therapeutic efficacy. The clinical success of antibodies like Teplizumab underscores the translational potential of antibody-based platforms. Looking forward, scFv-based biologics, particularly when integrated with humanized Fc domains and half-life extension technologies, offer a promising and customizable strategy for next-generation diabetes therapy, bridging innovative drug design with clinically meaningful metabolic and immune modulation.